0° sunny Silicon Beach

Corus Pharma

Acquired by: Gilead Sciences

Corus Pharma develops drugs to treat unmet needs in respiratory and infectious diseases. The company’s core competencies reside in the identification of drug candidates, rapid clinical development, and efficiently securing FDA approval for products. Corus management brings extensive executive and research experience from companies such as Pathogenesis, Genentech, and Bristol-Myers Squibb.